Citations

Clear

4610 citation(s) found for "Lu, Brian".

Pavilion Lake Microbialites: Morphological, Molecular and Biochemical Evidence for a Cold-Water Transition to Colonial Aggregates
Schulze‐Makuch, Dirk , Lim, D. S. S. , Laval, B. , Turse, Carol, Walther-António, Marina , Chan, Olivia, Brady, Allyson L. , Reid, Donnie, Irwin, Louis N. , Pointing, Stephen Brian , Reid, Don, Walther-Antonio, Marina

Mayo Clinic

Life | December 27, 2012 | Volume: 3 | Issue: 1 | Pages: 21-37

10.3390/life3010021 | PMID 25371330 Get It

The presence of microbialite structures in a freshwater, dimictic mid-latitudelake and their establishment after the last ice age about 10,000 years ago is puzzling.Freshwater calcite microbialites at Pavilion Lake, British Columbia, Canada, consist of acomplex community of microorganisms that collectively form large, ordered structuredaggregates. This distinctive assemblage of freshwater calcite microbialites was studied through standard microbial methods, morphological observations, phospholipid fatty acid(PLFA) analysis, DNA sequencing and the identification of quorum sensing molecules.Our results suggest that the microbialites may represent a transitional form from theexclusively prokaryotic colonial precursors of stromatolites to the multicellular organismicaggregates that give rise to coral reefs.
Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates
Linder, Brian J. , Frank, Igor, Umbreit, Eric , Shimko, Mark, Rangel, Laureano J. , Karnes, R. Jeffrey , Fernández, Nicolás , Linder, Brian J

Mayo Clinic

International Journal of Urology | December 22, 2012 | Volume: 20 | Issue: 9 | Pages: 860-864

10.1111/iju.12061 | PMID 23278942 Get It

ObjectivesTo examine the ability of standard and saturation transrectal prostate biopsy techniques to predict appropriate candidates for active surveillance.MethodsBetween 2005 and 2007, 500 consecutive patients underwent transrectal ultrasound‐guided biopsy by a standard template (12 cores) or saturation template (≥18 cores, median 27 cores), with subsequent radical prostatectomy. Using the criteria of Gleason score ≤6, clinical stage T1 or T2a, prostate‐specific antigen <10 and ≤33% of cores involved, 218 patients were potential candidates for active surveillance. Pathology results from the prostatectomy specimens were used to determine the accuracy of each biopsy technique. Biochemical failure after prostatectomy was evaluated using logistic and Cox proportional hazards regression.ResultsA standard biopsy was carried out for 124 patients and saturation biopsy for 94 patients. There was no statistically significant difference between the groups in terms of median age (P = 0.14), preoperative prostate‐specific antigen (P = 0.52) and clinical stage (P = 0.23). Similar rates of Gleason score ≥7 at the time of radical prostatectomy were found, with 14% for standard biopsy and 15% for saturation biopsy (P = 0.70). Upstaging was shown in two standard biopsy patients (1.6%) and no saturation biopsy patients (P = 0.62). A multivariate analysis adjusting for prior prostate biopsy, preoperative prostate‐specific antigen and clinical stage showed no difference in the rate of upgrading based on biopsy technique (P = 0.26). During follow up, 5‐year biochemical failure‐free survival estimates were not significantly different (P = 0.11).ConclusionsIn men with prostate cancer, standard and saturation transrectal prostate biopsies techniques are equally predictive of candidates for active surveillance.
Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high‐risk prostate cancer
Linder, Brian J. , Boorjian, Stephen A. , Umbreit, Eric , Carlson, Rachel E. , Rangel, Laureano J. , Bergstralh, Eric J., Karnes, R. Jeffrey , Linder, Brian J

Mayo Clinic

International Journal of Urology | December 22, 2012 | Volume: 20 | Issue: 8 | Pages: 798-805

10.1111/iju.12047 | PMID 23278850 Get It

BackgroundTo evaluate the impact of adjuvant hormonal therapy after radical prostatectomy on overall survival in high‐risk prostate cancer patients, stratified by comorbidity status.MethodsWe identified 1247 patients who underwent radical prostatectomy from 1988 to 2004 for high‐risk prostate cancer, as defined by National Comprehensive Cancer Network classification. Comorbidity status was stratified by Charlson Comorbidity Index as 0, 1 or >2, as well as by the presence or absence of cardiovascular disease. Overall survival was estimated by the Kaplan–Meier method, and compared within each comorbidity category/adjuvant hormonal therapy strata with the log–rank test.ResultsMedian patient age was 65 years, and the median postoperative follow up was 11.2 years. In total, 419 patients (34%) received adjuvant hormonal therapy. The distribution of Charlson Comorbidity Index was 0, 1 and ≥2 in 861 (69%), 244 (20%) and 142 (11%) patients, respectively. The 10‐year overall survival for patients who received adjuvant hormonal therapy versus those who did not was 75% versus 82% (P = 0.54) for patients with Charlson Comorbidity Index = 0, 72% versus 76% (P = 0.83) with Charlson Comorbidity Index = 1, and 70% versus 68% (P = 0.33) with Charlson Comorbidity Index ≥2. Meanwhile, 155 (12%) patients had cardiovascular disease, and the 10‐year overall survival for patients with cardiovascular disease who received adjuvant hormonal therapy was 72%, compared with 76% without adjuvant hormonal therapy (P = 0.97). On multivariate analysis, receipt of adjuvant hormonal therapy was not associated with non‐prostate cancer mortality (P = 0.24).ConclusionsAdjuvant hormonal therapy after radical prostatectomy for high‐risk prostate cancer does not increase non‐prostate cancer mortality, even among patients with multiple comorbidities. Additional studies are warranted to determine optimal multimodal treatment approach for high‐risk patients.
Robotic Transvesical Rectourethral Fistula Repair After a Robotic Radical Prostatectomy
Frank, Igor, Dozois, Eric J. , Elliott, Daniel S. , Linder, Brian J.

Mayo Clinic

Videourology™ | December 20, 2012 | Volume: 27 | Issue: 1 | Pages: No page available

10.1089/vid.2012.0043 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2012.0043.M1 sj-vid-1-vid-10.1089_vid.2012.0043
Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies
Loeb, Stacy , Hu, Qiaoyan, Cooper, Phillip R. , Roehl, Kimberly A., McGuire, Barry B. , Baumann, N, Catàlona, William J. , Helfand, Brian T. , Loeb, Stacy

Mayo Clinic

Journal of Urology | December 14, 2012 | Volume: 189 | Issue: 5 | Pages: 1697-1701

10.1016/j.juro.2012.12.023 | PMID 23246478 Get It

A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation
Bartos, Daniel C. , Anderson, Jeffrey , Bastiaenen, Rachel , Johnson, Jonathan N. , Gollob, Michael H. , Tester, David J. , Burgess, Don E. , Homfray, Tessa , Behr, Elijah R. , Ackerman, Michael J. , Guicheney, Pascale , Delisle, Brian P. , Behr, Elijah Raphael , Gollob, Michael H

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 11, 2012 | Volume: 24 | Issue: 5 | Pages: 562-569

10.1111/jce.12068 | PMID 23350853 Get It

R231H Causes a High Penetrance for Familial AFBackgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence is expected to grow. A genetic predisposition for AF has long been recognized, but its manifestation in these patients likely involves a combination of rare and common genetic variants. Identifying genetic variants that associate with a high penetrance for AF would represent a significant breakthrough for understanding the mechanisms that associate with disease.Method and ResultsCandidate gene sequencing in 5 unrelated families with familial AF identified the KCNQ1 missense mutation p.Arg231His (R231H). In addition to AF, several of the family members have abnormal QTc intervals, syncope or experienced sudden cardiac arrest or death. KCNQ1 encodes the voltage‐gated K+ channel that conducts the slowly activating delayed rectifier K+ current in the heart. Functional and computational analyses suggested that R231H increases KCNQ1 current (IKCNQ1) to shorten the atrial action potential (AP) duration. R231H is predicted to minimally affect ventricular excitability, but it prevented the increase in IKCNQ1 following PKA activation. The unique properties of R231H appeared to be caused by a loss in voltage‐dependent gating.ConclusionsThe R231H variant causes a high penetrance for interfamilial early‐onset AF. Our study indicates R231H likely shortens atrial refractoriness to promote a substrate for reentry. Additionally, R231H might cause abnormal ventricular repolarization by disrupting PKA activation of IKCNQ1. We conclude genetic variants, which increase IKs during the atrial AP, decrease the atrial AP duration, and/or shorten atrial refractoriness, present a high risk for interfamilial AF.
Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, Chen , Steplowski, Emily, Brotzman, Michelle, Xu, Mousheng, Mudgal, Poorva, Ámundadóttir, Laufey T. , Arslan, Alan A. , Bueno‐de‐Mesquita, H. Bas, Gross, Myron D., Helzlsouer, Kathy J., Jacobs, Eric J. , Petersen, Gloria M. , Zheng, Wei , Buring, Julie E. , Canzian, Federico , Cao, Guangwen , Duell, Eric J. , Elena, Joanne W. , Gaziano, J. Michael , Giovannucci, Edward L. , Hallmans, Göran, Hutchinson, Amy , Hunter, David J., Jenab, Mazda , Jiang, Guoliang , LaCroix, Andrea Z. , Li, Zhaoshen , Mendelsohn, Julie B., Panico, Salvatore , Patel, Alpa V. , Qian, Zhi Rong , Ríboli, Elio , Sesso, Howard D. , Shen, Hongbing , Shu, Xiao‐Ou , Tjønneland, Anne , Tobias, Geoffrey S. , Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala , Wactawski‐Wende, Jean , Wang, Chengfeng , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Hartge, Patricia, Fuchs, Charles S. , Lin, Dongxin , Wolpin, Brian M. , Kraft, Peter , Stolzenberg‐Solomon, Rachael Z. , Kooperberg, Charles , Albanes, Demetrius , Boutron‐Ruault, Marie‐Christine , Khaw, Kay‐Tee , Chanock, Stephen Jacob , Amundadottir, Laufey , Duell, Eric J , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Shu, Xiao-Ou , Visvanathan, Kala , Jenab, Mazda , Zheng, Wei , Cao, Guangwen , Riboli, Elio , Zeleniuch-Jacquotte, Anne , Shen, Hongbing

Mayo Clinic

Gut | November 24, 2012 | Volume: 63 | Issue: 1 | Pages: 152-160

10.1136/gutjnl-2012-303477 | PMID 23180869 Get It

Background and objective Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. Methods We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional hazards regression was used in an additive genetic model with adjustment for age, sex, clinical stage and the top four principal components of population stratification. The first stage included 642 cases of European ancestry (PanScan), from which the top SNPs (p≤10 −5 ) were advanced to a joint analysis with 363 additional patients from China (ChinaPC). Results In the first stage of cases of European descent, the top-ranked loci were at chromosomes 11p15.4, 18p11.21 and 1p36.13, tagged by rs12362504 (p=1.63×10 −7 ), rs981621 (p=1.65×10 −7 ) and rs16861827 (p=3.75×10 −7 ), respectively. 131 SNPs with p≤10 −5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; p=1.72×10 −7 ) on chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The HR (95% CI) for death was 0.74 (0.66 to 0.84) in PanScan I, 0.79 (0.65 to 0.97) in ChinaPC and 0.76 (0.68 to 0.84) in the joint analysis. Conclusions Germline genetic variation in the SBF2 locus was associated with overall survival in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association should be investigated in additional large patient cohorts.
Assessing the Available Techniques for Testing Myocardial Viability: What Does the Future hold?
Shapiro, Brian P. , Mergo, Patricia J. , Austin, Christopher , Kantor, Birgit, Gerber, Thomas C.

Mayo Clinic

Future Cardiology | November 23, 2012 | Volume: 8 | Issue: 6 | Pages: 819-836

10.2217/fca.12.59 | PMID 23176686 Get It

Use of supramaximal stimulation to predict facial nerve outcomes following vestibular schwannoma microsurgery: results from a decade of experience
Schmitt, William R., Daube, Jasper R., Carlson, Matthew L. , Mandrekar, Jayawant N. , Beatty, Charles W., Neff, Brian A., Driscoll, Colin L. W., Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | November 9, 2012 | Volume: 118 | Issue: 1 | Pages: 206-212

10.3171/2012.10.jns12915 | PMID 23140153 Get It

Object The goal of vestibular schwannoma surgery is tumor removal and preservation of neural function. Intraoperative facial nerve (FN) monitoring has emerged as the standard of care, but its role in predicting long-term facial function remains a matter of debate. The present report seeks to describe and critically assess the value of applying current at supramaximal levels in an effort to identify patients destined for permanent facial paralysis. Methods Over more than a decade, the protocol for stimulating and assessing the FN during vestibular schwannoma surgery at the authors' institution has consisted of applying pulsed constant-current stimulation at supramaximal levels proximally and distally following tumor resection to generate an amplitude ratio, which subtracted from 100% yields the degree to which the functional integrity of the FN “dropped off” intraoperatively. These data were prospectively collected and additional variables that might impact postoperative FN function were retrospectively reviewed from the medical record. Only patients with anatomically intact FNs and > 12 months of follow-up data were analyzed. Results There were 267 patients available for review. The average posterior fossa tumor diameter was 24 mm and the rate of long-term good (House-Brackmann Grade I–II) FN function was 84%. Univariate logistic regression analysis revealed that prior treatment, neurofibromatosis Type 2 status, tumor size, cerebellopontine angle extension, subjectively thinned FN at the time of operation, minimal stimulation threshold, percent dropoff by supramaximal stimulation (SMS), and postoperative FN function all correlated statistically (p < 0.05) with long-term FN function. When evaluating patients with significant FN weakness at the time of hospital discharge, only the percent dropoff by SMS remained a significant predictor of long-term FN function. However, the positive predictive value of SMS for long-term weakness is low, at 46%. Conclusions In a large cohort of patients, the authors found that interrogating intraoperative FN function with SMS is safe and technically simple. It is useful for predicting which patients will ultimately have good facial function, but is very limited in identifying patients destined for long-term facial weakness. This test may prove helpful in the future in tailoring less than gross-total tumor removal to limit postoperative facial weakness.